This website is intended for healthcare professionals only

Trending Topic

Close-up of a person rubbing their temple, depicting persistent headache pain
13 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Migraines profoundly impact well-being, especially in children and adolescents. From 1990 to 2021, global pediatric migraine disability has increased, with particular vulnerability in females and adolescents aged 15–19.1 A 2023 meta-analysis found the prevalence of primary headache diagnosis in individuals aged 8–18 years to be 62%.2 The prevalence of a migraine diagnosis was 11%; 8% […]

James Howard, AAN 2022: Unmet needs in the treatment of myasthenia gravis

3 mins
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: May 12th 2022

Myasthenia gravis (MG) is a rare autoimmune disorder caused by antibodies that act against the myoneural junction, resulting in weakness of the skeletal muscles. Prof. James Howard (The University of North Carolina at Chapel Hill, CA, USA) discusses the unmet needs in the treatment of this rare disease, including, quality of life of patients, response to treatment regimens, approved paediatric treatments, and treatments in pregnant women and family planning.

View more content from Prof. James Howard: Ravulizumab for adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis – Results from the phase 3 CHAMPION-MG OLE trial

Questions:

  1. What are the unmet needs in the treatment of myasthenia gravis (MG)? (0:19)

Disclosures: James Howard receives grant/research Support from Alexion Pharmaceuticals, argenx BVBA, Cartesian Therapeutics, the Centers for Disease Control and Prevention (Atlanta, GA, USA), the Myasthenia Gravis Foundation of America, the Muscular Dystrophy Association, the National Institutes of Health (including the National Institute of Neurological Disorders and Stroke and the National Institute of Arthritis and Musculoskeletal and Skin Diseases), PCORI, Ra Pharmaceuticals (now UCB Biosciences), and Takeda Pharmaceuticals; he is on the advisory Board for Alexion Pharmaceuticals, argenx BVBA, and Ra Pharmaceuticals (now UCB Biosciences); and is a major stock shareholder in GlaxoSmithkline, JNJ, and Pfizer.

Support:  Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.

Filmed as a highlight of AAN 2022

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup